AMLX — Amylyx Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Amylyx Pharmaceuticals Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Amylyx Pharmaceuticals Prices Public Offering Of Common Stock
Brief: Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Amylyx Pharmaceuticals Reports Q3 2024 Financial Results
Brief: Amylyx Pharmaceuticals Q3 EPS USD -1.07 Vs. IBES Estimate USD -0.71
U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma
Amylyx rises after positive data from genetic disorder drug trial
Brief: Amylyx Pharmaceuticals Announces Positive Topline Results From Phase 2 Helios Clinical Trial Demonstrating Sustained Improvements With AMX0035 In People Living With Wolfram Syndrome
Amylyx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Amylyx Pharmaceuticals Q2 EPS USD -1.07
Amylyx Pharmaceuticals Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Amylyx Pharmaceuticals Receives Orphan Drug Designation From The European Commission For Amx0035
Amylyx climbs after completing acquisition of low blood sugar drug
Amylyx climbs after completing acquisition of low blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Acquisition Of Phase 3-Ready GLP-1 Receptor Antagonist (Avexitide) With FDA Breakthrough Therapy Designation
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Amylyx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary